Neostig (Neostigmine Methylsulfate)

Neostigmine methylsulfate reversibly blocks acetylcholinesterase, the enzyme that degrades acetylcholine. By inhibiting this enzyme, acetylcholine accumulates at neuromuscular junctions, enhancing cholinergic transmission and improving muscle contraction and gut motility.

The dose of Neostig is individualized and determined by the prescribing clinician based on the indication, patient weight, renal function, and response. Healthcare professionals adjust the amount to achieve the desired therapeutic effect while monitoring for adverse reactions.

Safety data for neostigmine methylsulfate in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Neostig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

The most common alternative is pyridostigmine, another reversible acetylcholinesterase inhibitor taken orally for chronic myasthenia gravis. Neostig is administered parenterally, offering rapid onset for acute reversal of neuromuscular blockade, whereas pyridostigmine provides longer‑acting oral maintenance therapy.

Neostig should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Neostig is supplied as a sterile injectable solution and may be given intramuscularly, intravenously, or subcutaneously by a qualified healthcare professional. The route and rate of administration depend on the clinical indication and the patient’s condition.

Serious adverse events include bradycardia, severe hypotension, bronchospasm, cholinergic crisis leading to respiratory failure, and seizures. Prompt recognition and immediate medical intervention are essential if any of these symptoms develop.

Neostig is contraindicated in patients with known hypersensitivity to neostigmine or any formulation component, in those with severe asthma or active bronchospasm, and in individuals with significant cardiac conduction disorders such as complete heart block unless a pacemaker is in place.